Telehealth Vs In-Person TRT: How The Two Models Compare

Telehealth vs in-person TRT comes down to how care is delivered, not whether the clinical standard changes. Both models require two early-morning total testosterone measurements confirmed below the diagnostic threshold, combined with symptoms, before a provider can prescribe testosterone (Mulhall et al., 2018). The American Urological Association and the Endocrine Society apply the same diagnostic and monitoring criteria regardless of whether the visit happens by video or in an exam room (Bhasin et al., 2018).

For men considering direct-pay lab testing as a first step, understanding what each care channel covers and where each one falls short is a practical question with real regulatory stakes. Testosterone is a Schedule III controlled substance under the Anabolic Steroid Control Act. A valid prescription requires a legitimate medical purpose, clinical evaluation, and lab confirmation. The pathway to that prescription looks different depending on the model.

Telehealth vs in-person TRT is the comparison between remote video-based testosterone care and traditional office-based treatment. Both models are expected to follow the same AUA and Endocrine Society guidelines for diagnosis, prescribing, and monitoring. The difference is the delivery channel, not the clinical standard.

Venous blood draw for testosterone testing at a local lab

What Does the AUA Require for a TRT Diagnosis?

The AUA guideline requires two separate early-morning total testosterone measurements combined with signs or symptoms of deficiency before a diagnosis of testosterone deficiency is made (Mulhall et al., 2018). This applies whether the evaluation takes place in a urology office, a primary care setting, or through a licensed telehealth provider. A single low reading is not enough.

The Endocrine Society adds a recommendation for free testosterone measurement when total testosterone is near the lower limit of normal or when sex hormone-binding globulin (SHBG) is suspected to be altered (Bhasin et al., 2018). Both guidelines require LH and FSH testing to distinguish primary from secondary hypogonadism. These steps don't change with the visit modality.

Clients ordering labs through a telehealth provider can complete the required blood draws at a local lab, often at a Quest or Labcorp location, after following standard test preparation steps. The results are reviewed remotely, and the provider applies the same clinical criteria. A pre-therapy panel that includes total testosterone, free testosterone, SHBG, LH, FSH, hematocrit, and PSA satisfies the guideline-directed workup for both models.

How Does Telehealth TRT Work in Practice?

A review in the International Journal of Impotence Research examined the benefits and limitations of managing TRT through telemedicine (Dubin et al., 2022). The authors proposed a framework where telehealth covers history-taking, symptom assessment, laboratory orders, medication counseling, and follow-up visits. A separate practice-comparison study found that direct-to-consumer telehealth platforms followed AUA guidelines in their evaluation and treatment of testosterone deficiency (Jesse et al., 2022). The 2024 SMSNA/AUA telemedicine and men's health white paper built on these findings, recommending a hybrid model that uses telemedicine for most routine management while reserving in-person visits for the initial sexual-health physical examination, testicular evaluation, and procedures requiring in-office presence (SMSNA/AUA, 2024).

In a telehealth model, the client typically completes an intake questionnaire, orders lab work through individual biomarker tests or bundled panels, visits a local draw site, and then meets with a licensed provider by video to review results. If the labs confirm testosterone deficiency and the clinical picture supports treatment, the provider discusses risks, benefits, and alternatives with the client before prescribing. Medication is then shipped to the client's address.

Follow-up labs are ordered on the same cadence as in-person care. The AUA recommends measuring testosterone levels every 6-12 months during therapy, along with hematocrit and other safety markers (Mulhall et al., 2018). A CBC with differential tracks hematocrit, and a PSA test covers prostate screening where indicated.

What Can an In-Person Visit Do That Telehealth Cannot?

Physical examination is the most commonly cited gap. The AUA guideline includes testicular evaluation for varicocele, atrophy, or masses as part of the workup. Gynecomastia, prostate assessment by digital rectal exam, and body-composition changes are easier to evaluate in person. The SMSNA/AUA white paper specifically reserves these elements for in-person care (SMSNA/AUA, 2024).

In-person settings also offer direct injection training, procedural options (pellet insertion, for example, though Marek Diagnostics does not offer pellets), and real-time blood pressure measurement. The February 2025 FDA class-wide labeling update added a blood-pressure warning to all testosterone products, removed the prior cardiovascular boxed warning language after the TRAVERSE trial, and retained the Limitation of Use for age-related hypogonadism (FDA, 2025).

For men with complex presentations, secondary causes of hypogonadism, or findings that require specialist referral, an in-person evaluation may be necessary regardless of where ongoing management takes place.

How Do the Two Models Compare Side by Side?

Factor	Telehealth TRT	In-Person TRT
Diagnostic criteria	Same: two early-morning draws plus symptoms (AUA)	Same: two early-morning draws plus symptoms (AUA)
Physical exam	Limited; testicular and prostate evaluation may require referral	Available on-site
Lab ordering and review	Remote ordering, local draw, video review	On-site or referral lab, in-person review
Monitoring cadence	Every 6-12 months per AUA guidelines	Every 6-12 months per AUA guidelines
Medication delivery	Shipped to client	Picked up or administered in office
Geographic reach	Available across state lines where licensed (state rules vary)	Limited to the provider's physical location
Scheduling flexibility	Evenings and weekends common	Weekday business hours typical
Physical exam capacity	History, labs, counseling; not hands-on exam	Full physical exam available
Controlled-substance prescribing	Permitted under temporary federal flexibility through Dec 31, 2026	Standard DEA prescribing rules apply

What Are the Current Federal Rules for Prescribing TRT Online?

Testosterone is a Schedule III controlled substance. Under the Ryan Haight Act, a prior in-person medical evaluation is generally required before a controlled substance can be prescribed via the internet. During the COVID-19 pandemic, federal agencies granted temporary exceptions to this rule for telemedicine.

The DEA and HHS issued the Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities (90 Fed. Reg. 61301), effective January 1, 2026, through December 31, 2026 (DEA/HHS, 2025). Under this extension, DEA-registered practitioners can prescribe Schedule III testosterone via audio-video telemedicine without a prior in-person evaluation, provided other federal and state requirements are met.

This flexibility is temporary. A permanent Special Registration for Telemedicine rule has not been finalized, though a final rule was sent to the Office of Information and Regulatory Affairs in August 2026. After December 31, 2026, the prior in-person evaluation default under the Ryan Haight Act is expected to resume unless the extension is renewed or a permanent rule takes effect.

State licensure, informed-consent, and telemedicine rules also vary. A provider licensed in one state may not be able to treat a client in another. Controlled-substance shipping permissions differ by jurisdiction.

Does the TRAVERSE Trial Apply to Both Models?

Yes. The TRAVERSE trial enrolled 5,246 men aged 45-80 with hypogonadism and existing cardiovascular disease or high cardiovascular risk. The primary endpoint showed that major adverse cardiac events occurred in 7.0% of the testosterone group versus 7.3% of the placebo group (hazard ratio 0.96, 95% CI 0.78-1.17), meeting noninferiority criteria (Lincoff et al., 2023).

Secondary signals showed higher rates of atrial fibrillation (3.5% vs 2.4%), pulmonary embolism (0.9% vs 0.5%), and acute kidney injury (2.3% vs 1.5%) in the testosterone group. Nonfatal arrhythmias requiring intervention were also higher (5.2% vs 3.3%).

These findings apply to TRT prescribed through any channel. A provider using telehealth bears the same obligation to monitor for the cardiovascular findings noted in TRAVERSE, including atrial fibrillation and pulmonary embolism, as a provider working in an office-based practice. Monitoring labs for men on therapy typically include hematocrit and PSA where indicated (Bhasin et al., 2018; Mulhall et al., 2018). Some providers also track sensitive estradiol when symptoms suggest aromatization. Elevated hematocrit is flagged by guidelines as a marker that may prompt a provider to adjust therapy or consider phlebotomy.

What Questions Should Clients Ask Before Choosing a Model?

Regardless of the delivery channel, a few clinical questions matter before starting TRT.

Will the provider order a full baseline panel before prescribing, including total testosterone by a validated assay, free testosterone, SHBG, LH, FSH, hematocrit, and PSA where indicated? How often will follow-up labs be drawn, and which markers will be tracked?

Is a physical exam included, or will the provider arrange a referral for testicular and prostate evaluation?

Has the provider discussed fertility? Exogenous testosterone suppresses spermatogenesis, and recovery after stopping is variable, not guaranteed.

What happens after December 31, 2026, if the federal telemedicine flexibility expires and a permanent rule isn't in place? And is the testosterone product FDA-approved for hypogonadism, or is it compounded? Compounded testosterone is not FDA-approved.

For clients choosing telehealth, a bundled lab panel that covers the guideline-directed markers can simplify the baseline workup. Ordering SHBG alongside total testosterone gives the provider the data to calculate or measure free testosterone when binding-protein levels are abnormal.

Where Does Telehealth vs in-Person TRT Stand Going Forward?

The clinical evidence supports both models when guideline-directed care is followed. No large randomized trial has directly compared clinical outcomes of telehealth versus in-person testosterone therapy for diagnosed hypogonadism. The available data, including the Dubin et al. 2022 review and the SMSNA/AUA 2024 white paper, point toward a hybrid approach: telehealth for the routine elements (history, counseling, lab review, prescription management) and in-person visits for the components that require hands-on evaluation.

The regulatory picture is less settled. The current federal telemedicine flexibility for Schedule III prescribing expires at the end of 2026, and its renewal or replacement is not confirmed. Clients considering telehealth-based testing should ask their provider about continuity-of-care planning, especially if state rules add additional requirements.

Telehealth vs in-person TRT is not a question of which model is clinically superior. Both must meet the same diagnostic threshold, the same monitoring schedule, and the same safety standards. The question for each individual is which model fits their clinical needs, geographic situation, and comfort with the regulatory timeline.

Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.

FAQs

Can testosterone be prescribed through telehealth without an in-person visit?

Through December 31, 2026, DEA-registered practitioners may prescribe Schedule III testosterone via audio-video telemedicine without a prior in-person evaluation under the Fourth Temporary Extension (90 Fed. Reg. 61301). After that date, the prior in-person evaluation default under the Ryan Haight Act is expected to resume unless extended or replaced.

Are the diagnostic criteria for low testosterone different for telehealth versus in-person care?

No. Both models require two early-morning total testosterone measurements combined with symptoms or signs of deficiency. The AUA and Endocrine Society guidelines apply the same criteria regardless of visit modality (Mulhall et al., 2018; Bhasin et al., 2018).

What monitoring is required once telehealth vs in-person TRT begins?

The AUA recommends measuring testosterone levels every 6-12 months on therapy, plus hematocrit, PSA where indicated, and other safety labs. This schedule applies to both telehealth and in-person models (Mulhall et al., 2018).

Does the TRAVERSE trial apply to telehealth TRT the same as in-person TRT?

Yes. TRAVERSE found noninferiority for major adverse cardiac events (7.0% vs 7.3%) but higher rates of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group (Lincoff et al., 2023). These safety findings apply to testosterone prescribed through any channel.

When is an in-person visit still needed for TRT?

Physical examination for testicular abnormalities, varicocele, gynecomastia, or prostate evaluation is part of the guideline-directed workup and typically requires an in-person visit or referral. The SMSNA/AUA white paper recommends reserving these elements for in-person care (SMSNA/AUA, 2024).

What happens to telehealth TRT prescriptions after December 31, 2026?

The current federal flexibility ends. A permanent Special Registration rule has not been finalized. Clients and providers should plan for the possibility that the prior in-person evaluation requirement under the Ryan Haight Act resumes unless extended.

Your cart is currently empty.